Skip to main content
All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q3 report for Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) on October 20, 2025, reporting $80,000 in lobbying income.

Lobbying for Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) · Pharmaceutical company.

As filed: TIBER CREEK GROUP for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY).

All filings by Tiber Creek Group · Everything Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$80,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Health Issues

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding.

Copyright/Patent/Trademark

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

 Bills named in this filing 4
  • H.R. 4231
    Treat and Reduce Obesity Act of 2025
  • S. 1973
    Treat and Reduce Obesity Act of 2025
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem